Thermo Fisher Scientific D&A increased by 28.2% to $291.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 4.3%, from $304.00M to $291.00M. Over 4 years (FY 2021 to FY 2025), D&A shows an upward trend with a 6.0% CAGR.
Higher levels typically reflect significant historical capital expenditures or acquisitions that are now being expensed over time.
This metric represents the non-cash accounting charges used to allocate the cost of tangible assets and intangible asset...
Capital-intensive hardware manufacturers generally show higher D&A relative to revenue than pure-play software companies.
cf_depreciation_and_amortization| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $211.00M | $205.00M | $217.00M | $250.00M | $236.00M | $244.00M | $256.00M | $253.00M | $270.00M | $269.00M | $276.00M | $285.00M | $276.00M | $291.00M | $304.00M | $276.00M | $256.00M | $227.00M | $291.00M |
| QoQ Change | — | -2.8% | +5.9% | +15.2% | -5.6% | +3.4% | +4.9% | -1.2% | +6.7% | -0.4% | +2.6% | +3.3% | -3.2% | +5.4% | +4.5% | -9.2% | -7.2% | -11.3% | +28.2% |
| YoY Change | — | — | — | — | +11.8% | +19.0% | +18.0% | +1.2% | +14.4% | +10.2% | +7.8% | +12.6% | +2.2% | +8.2% | +10.1% | -3.2% | -7.2% | -22.0% | -4.3% |